Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
PFE · NYSE · United States · Pharmaceutical Preparations
In shortPFIZER INC is profitable, generates cash and carries moderate debt, with revenue stable (−1.6% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | – | n/a |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 12.4% | 70/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 8.9% | 44/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.16× | 30/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.75× | 69/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 14.5% | 78/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.17× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 50.0% | 0/100 |
| Operating margin volatility | – | n/a |
Weight in the score: 20%
| Revenue growth, 3-year average | -14.8% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | -37.1% | 0/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 81,288 | 101,175 | 59,553 | 63,627 | 62,579 |
| Cost of revenue | 30,821 | 34,344 | 24,954 | 17,851 | 16,067 |
| Gross profit | 50,467 | 66,831 | 34,599 | 45,776 | 46,512 |
| Research & development | 10,360 | 11,428 | 10,679 | 10,822 | 10,437 |
| Selling, general & admin | 12,703 | 13,677 | 14,771 | 14,730 | 13,794 |
| Interest expense | 1,291 | 1,238 | 2,209 | 3,091 | 2,671 |
| Pre-tax income | 24,311 | 34,729 | 1,058 | 8,023 | 7,520 |
| Income tax | 1,852 | 3,328 | (1,115) | (28) | (266) |
| Net income | 21,979 | 31,372 | 2,119 | 8,031 | 7,771 |
| Diluted EPS | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 |
| Diluted shares (millions) | 5,708 | 5,733 | 5,709 | 5,700 | 5,713 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of PFIZER INC are included in the Investor plan. Try free for 7 days →
Not computed: a required balance-sheet item is missing.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 28, 2026 · Data updated Aug 4, 2026